In Europe, the European Medicines Agency has just confirmed that they’re currently in the process of investigating a rare and serious blood condition that has arisen for people who received the Moderna vaccine. And this is not the only challenge that Moderna is currently facing. On Tuesday, the French Health Authority released a new public advisory…
Facts Matter (Nov. 12): Regulators Probe ‘Rare and Serious’ Blood Clots; FDA Recalls 2M Tests Over False Positives
NIH Says Moderna Wrongly Left Off Government Scientists From COVID-19 Vaccine Patent
The National Institutes of Health (NIH) and Moderna are engaged in a dispute over which scientists developed Moderna’s COVID-19 vaccine, with the conflict possibly heading to court. Moderna and government scientists collaborated on the development of the shot and the government asked the company to include a trio of scientists on its patent application. But…
Regulator Investigating Moderna Vaccine Over ‘Rare’ but Serious Blood Condition
Europe’s drug regulator on Thursday confirmed it is investigating reports of a blood condition in recipients of Moderna’s mRNA COVID-19 vaccine. According to a bulletin posted by the European Medicines Agency (EMA), it is reviewing six cases capillary leak syndrome, considered a “very rare disorder,” after they were reported in the EMA’s EudraVigilance database. “At this…
Regulator Reviewing Reports of ‘Rare’ and Serious Condition Linked to Moderna Vaccine
Europe’s drug regulator on Thursday confirmed it is investigating reports of a blood condition in recipients of Moderna’s mRNA COVID-19 vaccine. According to a bulletin posted by the European Medicines Agency (EMA), it is reviewing six cases capillary leak syndrome, considered a “very rare disorder,” after they were reported in the EMA’s EudraVigilance database. “At this…
Moderna’s COVID-19 Vaccine Offers Better Protection, Higher Myocarditis Risk Than Pfizer’s: Company
November 11, 2021
admin
Business & EconomyCCP VirusCompaniesEditor's PicksHealth NewsMind & BodyModernaVaccineVaccines & Safety
0 Comment
Moderna on Thursday said its COVID-19 vaccine offers better protection against so-called breakthrough cases than its rival Pfizer’s jab, but also said that more cases of heart inflammation have been seen in people who received its shot. “A small increase in cases of myocarditis is seen with mRNA-1273 compared to BNT162b2 in males 12–29 years…
Germany Advises Against Moderna Shot for Young People Over Rare Heart Condition
German health authorities followed other European nations on Wednesday in advising against the use of Moderna’s Spikevax COVID-19 vaccine for people under the age of 30 after evidence emerged the shot has a slightly higher risk of cardiac inflammation. A German advisory committee, known as STIKO, cited findings similar to a study published on Nov. 8…
Effectiveness of 2 of 3 COVID-19 Vaccines Used in US Drops Below 50 Percent: Study
November 7, 2021
admin
AMERICACCP VirusHealth NewsJohnson JohnsonMind & BodyModernaPfizerScienceScience NewsUSUS NewsVaccines & Safety
0 Comment
The effectiveness of the three COVID-19 vaccines available in the United States has declined in recent months, with protection against infection falling under 50 percent for two of them, according to a new study. Moderna’s COVID-19 vaccine dropped from 89.2 percent in March to 58 percent in September, researchers found. During the same period of…
Effectiveness of 2 of 3 COVID-19 Vaccines Used in US Drops Below 50 Percent After 6 Months: Study
November 7, 2021
admin
AMERICACCP VirusHealth NewsJohnson JohnsonMind & BodyModernaPfizerScienceScience NewsUSUS NewsVaccines & Safety
0 Comment
The effectiveness of the three COVID-19 vaccines available in the United States has declined in recent months, with protection against infection falling under 50 percent for two of them after six months, according to a new study. Moderna’s COVID-19 vaccine dropped from 89.2 percent in March to 58 percent in September, researchers found. During the…
Moderna Stock Tumbles on Earnings Miss and Lower COVID-19 Vaccine Sales Forecast
November 4, 2021
admin
Business & EconomyCCP VirusCompaniesCOVID-19 vaccineearningsMarketsModernaUSUS NewsVaccines & SafetyWorld
0 Comment
Moderna shares fell by more than 17 percent in early trading Thursday after the company slashed its COVID-19 vaccine sales forecast for 2021 by up to $5 billion and announced lower-than-expected third-quarter revenues and profits. In an earnings announcement (pdf), released Nov. 4, Moderna reported total third-quarter revenue of $5 billion. While that was well…
‘Good Decision’: Experts React to FDA Pushing Back Decision on Moderna Vaccine for Kids
The choice to delay deciding whether or not to authorize Moderna’s COVID-19 vaccine for children has merit because of concerns about post-vaccination heart inflammation, experts said. U.S. drug regulators recently opted not to decide right now on authorization for Moderna’s shot for kids between 12 and 17, according to Moderna, which is also delaying plans…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`